VWA5A Rabbit Polyclonal Antibody

CAT#: TA364684

VWA5A rabbit polyclonal antibody

Product Images

Immunohistochemistry of paraffin-embedded Human cervical cancer tissue using TA364684 (VWA5A Antibody) at dilution 1/80 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human cervical cancer tissue using TA364684 (VWA5A Antibody) at dilution 1/80, treated with fusion protein. (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human lung cancer tissue using TA364684 (VWA5A Antibody) at dilution 1/80 (Original magnification: ×200)

• 

  Immunohistochemistry of paraffin-embedded Human lung cancer tissue using TA364684 (VWA5A Antibody) at dilution 1/80, treated with fusion protein. (Original magnification: ×200)

Specifications

Product Data

• Applications: IHC
• Recommended Dilution: IHC: 100-300
  Positive control: Human cervical cancer
  Predicted cell location: Cytoplasm
• Reactivities: Human
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: Fusion protein of human VWA5A
• Formulation: pH7.4 PBS, 0.05% NaN3, 40% Glycerol
• Concentration: lot specific
• Purification: Antigen affinity purification
• Conjugation: Unconjugated
• Storage: Store at -20°C.
• Stability: 1 year
• Database Link:
  UniProt ID O00534
• Background: VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80% of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A.